Fosun Pharmaceutical announced that on September 23, 2026, the holding subsidiary Fuhong Hanlin and Amberstone signed a “Cooperation and License Agreement”. Fuhong Hanlin was granted an exclusive license by Amberstone to carry out research, development, production and commercialization of two cooperative products globally and in all fields of human use, based on the T-MATE™ technology platform, for agreed targets. Fu Hong Han Lin should pay Amberstone up to US$236.16 million in down payment, R&D expenses, development and regulatory milestones for this cooperation, including: up to US$4 million in down payment; total R&D expenses, development and regulatory milestones of up to US$232.16 million, which will be paid according to the agreement according to R&D progress and PCC, clinical research, regulatory approval, and marketing progress. Based on the annual net sales of the cooperative products achieved in the licensed region, Fuhong Hanlin shall pay Amberstone a graduated sales milestone payment of up to US$652 million as agreed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.